Tin tức & Cập nhật

Empagliflozin provides a significant clinical benefit within 90 days and shows no safety concerns in patients hospitalized for acute heart failure (HF), according to results of the EMPULSE trial reported at the American Heart Association (AHA) Scientific Sessions 2021.

Weight gain in between pregnancies worsens the risk hypertensive disorders of pregnancy (HDP), a recent study has found.

Postoperative treatment with the oral factor XIa inhibitor milvexian could help prevent the incidence of venous thromboembolism (VTE) in patients undergoing elective knee arthroplasty, according to results of a phase II trial presented at AHA 2021.